RxDoctor Payments Data

Troy Hampton, DO

Family Medicine · Lancaster, OHNPI 1275536377

Payments from drug & device makers

$7,699in general payments, 2019–2025

Across 530 payments — averaging $14.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$758
  • Astellas Pharma US Inc$545
  • Lilly USA, LLC$451
  • Bayer$375
  • Grifols USA, LLC$362
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$7,62999%
  • Education$701%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,699 in reported general payments places this provider in the 90th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$225
Medicare patients
23
Services billed
28

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban86$77,158
OzempicSemaglutide49$68,736
Tresiba Flextouch U-200Insulin Degludec65$51,619
KerendiaFinerenone35$42,183
GlyxambiEmpagliflozin/Linagliptin41$40,078
RybelsusSemaglutide22$33,181
MounjaroTirzepatide26$27,152
XareltoRivaroxaban24$26,553
JardianceEmpagliflozin23$25,786
Repatha SureclickEvolocumab40$25,124
TrulicityDulaglutide23$24,901
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$22,368
JanuviaSitagliptin Phosphate19$22,126
CreonLipase/Protease/Amylase26$19,699
TradjentaLinagliptin17$17,461

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$758$101,91771 claims
Boehringer IngelheimGlyxambi, Jardiance, Tradjenta, Synjardy Xr$183$99,123101 claims
PfizerEliquis, Nurtec Odt$358$89,44397 claims
AbbVieCreon, Vraylar, Linzess, Synthroid$1,324$53,102103 claims
Lilly USA, LLCMounjaro, Trulicity$451$52,05449 claims
BayerKerendia$375$42,18335 claims
Johnson & JohnsonXarelto$284$26,55324 claims
MerckJanuvia, Dulera$214$25,37731 claims
GSKTrelegy Ellipta$90$22,36831 claims
AstraZenecaFarxiga$188$14,46912 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$246$13,28614 claims
Astellas Pharma US IncMyrbetriq$545$9,59812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Lancaster

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →